{"id":770491,"date":"2023-07-18T07:52:22","date_gmt":"2023-07-18T11:52:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/"},"modified":"2023-07-18T07:52:22","modified_gmt":"2023-07-18T11:52:22","slug":"acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/","title":{"rendered":"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Accomplished global leader\u00a0brings 20 years of immunology sales and marketing expertise.<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years.<\/em>\n      <\/p>\n<p>LOS ANGELES, July  18, 2023  (GLOBE NEWSWIRE) &#8212; ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately. Mr. Lock will report to Founder and Chief Executive Officer\u00a0Shao-Lee Lin, MD, PhD\u00a0and will serve on the Company\u2019s Senior Leadership Team.<\/p>\n<p>\u201cI am thrilled to welcome Ken to ACELYRIN,\u201d\u00a0said\u00a0Dr. Lin.\u00a0\u201cHe has decades of proven experience leading end-to-end commercial activities across the entire product lifecycle and has built high performing sales and marketing teams across numerous immunology brands. His deep domain knowledge and highly respected expertise will be vital as we continue to advance izokibep through registrational clinical trials across several indications and prepare for multiple, consecutive potential commercial launches\u00a0within the next few years. Importantly, Ken is aligned with our mission to develop clinically meaningful, differentiated medicines to address the significant unmet need that remains for patients. We look forward to adding his extensive expertise across a multitude of autoimmune and inflammatory diseases to ACELYRIN.\u201d<\/p>\n<p>Mr.\u00a0Lock\u00a0brings to ACELYRIN leading experience in the Dermatology and Rheumatology therapeutic areas, having most recently served as Chief Commercial Officer at\u00a0Arcutis Biotherapeutics. There, he\u00a0built and\u00a0led a team of\u00a0more than\u00a0130 people and was responsible for the commercial planning, organization and capability build, brand development,\u00a0market access\u00a0strategy\u00a0and launch of\u00a0Zoryve\u00ae,\u00a0a\u00a0treatment for plaque psoriasis.\u00a0Prior to that, Mr. Lock\u00a0held\u00a0sales\u00a0and marketing roles of increasing responsibility in the U.S. and globally at\u00a0Gilead Sciences,\u00a0Amgen and\u00a0Wyeth (now Pfizer).<\/p>\n<p>\u201cIt\u2019s an honor to join the talented and accomplished ACELYRIN leadership team at this important juncture in the company\u2019s growth trajectory. It\u2019s clear ACELYRIN has the vision, strategy, and growing base of talent to build a leading, sustainable biopharmaceutical company serving multiple, large global markets with clinically differentiated new medicines,\u201d said Mr. Lock. \u201cACELYRIN is exceptionally well-positioned to deliver the\u00a0innovation\u00a0patients deserve\u00a0and\u00a0potentially change the standard of care\u00a0across a range\u00a0of immunologic conditions.\u201d<\/p>\n<p>Mr. Lock\u00a0holds a\u00a0dual BS\u00a0and BA\u00a0in\u00a0Biochemistry\/Cell Biology\u00a0and Psychology\u00a0from the University of California,\u00a0San Diego\u00a0and\u00a0an MBA from Cornell University.<\/p>\n<p>\n        <strong>About ACELYRIN<\/strong><br \/>\n        <br \/>ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company \u2013 with additional operations in the San Francisco Bay area \u2013 focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating\u00a0the\u00a0development and commercialization of promising product candidates.<\/p>\n<p>\n        <strong>About Izokibep<\/strong><br \/>\n        <br \/>Izokibep\u00a0is\u00a0a small protein therapeutic designed to inhibit IL-17A with high\u00a0potency through tight binding affinity, the potential for\u00a0robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and\u00a0an albumin binding domain that results in improved pharmacokinetic (PK) properties.\u00a0Clinical trial data\u00a0support the hypothesis\u00a0that\u00a0these unique characteristics of izokibep\u00a0may provide clinically meaningful and differentiated\u00a0benefits for patients, including resolution of key manifestations of disease. Izokibep is being evaluated in multiple\u00a0late-stage\u00a0trials in moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA).<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements including, but not limited to, statements related to the advancement and expected timing of ACELYRIN\u2019s development activities including Phase 3 programs; the therapeutic potential of ACELYRIN\u2019s product candidates including its ability to offer clinically meaningful, differentiated benefits for patients; and other statements that are not historical fact. These are based on ACELYRIN\u2019s current plans, objectives and projections, and are inherently subject to risks and uncertainties that may cause actual results to materially differ from those anticipated in such forward-looking statements. Such risks and uncertainties include those associated with the successful completion of development and regulatory activities with respect to ACELYRIN\u2019s product candidates, and other risks and uncertainties affecting ACELYRIN and its business, including those described from time to time under the caption \u201cRisk Factors\u201d and elsewhere in ACELYRIN\u2019s current and future reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. Forward-looking statements contained in this press release are made as of this date, and ACELYRIN undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Tyler Marciniak,<br \/>Vice President of Investor Relations,<br \/>Communications and Corporate Operations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uID33cpa8MK2ny9F3JX5sjgunpxu5Ol2Auok9gCPgvKNq_rv0r6qAO5fipfiblt792HU1dBt3IiA7SEFyoVTcH9Y9REzJ2hbhHBjzA1wuYY=\" rel=\"nofollow noopener\" target=\"_blank\"><u>investors@acelyrin.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w1Qi9dKmPufECU0Jzo2boPrRh-_WK8v2Cu4QMl2mQx28GLEsKJNguZxyuVOe86pIuLF588lMzvnTlJHq1Dfp9f7mOoTWUVBUiOiolNg3Yio=\" rel=\"nofollow noopener\" target=\"_blank\"><u>media@acelyrin.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Zjk4MjBmZGUtMTFlMy00YThlLWJjMjQtNzE2ODczMzQzMDQ3LTEyNzA0Mjk=\/tiny\/Acelyrin-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Accomplished global leader\u00a0brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years. LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) &#8212; ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately. Mr. Lock will report to Founder and Chief Executive Officer\u00a0Shao-Lee Lin, MD, PhD\u00a0and will serve on the Company\u2019s Senior Leadership Team. \u201cI am thrilled to welcome Ken to ACELYRIN,\u201d\u00a0said\u00a0Dr. Lin.\u00a0\u201cHe has decades of proven experience leading end-to-end commercial activities across the entire product lifecycle and has built high &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-770491","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Accomplished global leader\u00a0brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years. LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) &#8212; ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately. Mr. Lock will report to Founder and Chief Executive Officer\u00a0Shao-Lee Lin, MD, PhD\u00a0and will serve on the Company\u2019s Senior Leadership Team. \u201cI am thrilled to welcome Ken to ACELYRIN,\u201d\u00a0said\u00a0Dr. Lin.\u00a0\u201cHe has decades of proven experience leading end-to-end commercial activities across the entire product lifecycle and has built high &hellip; Continue reading &quot;ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-18T11:52:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0\",\"datePublished\":\"2023-07-18T11:52:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/\"},\"wordCount\":779,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/\",\"name\":\"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=\",\"datePublished\":\"2023-07-18T11:52:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0 - Market Newsdesk","og_description":"Accomplished global leader\u00a0brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years. LOS ANGELES, July 18, 2023 (GLOBE NEWSWIRE) &#8212; ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Ken Lock as Chief Commercial Officer, effectively immediately. Mr. Lock will report to Founder and Chief Executive Officer\u00a0Shao-Lee Lin, MD, PhD\u00a0and will serve on the Company\u2019s Senior Leadership Team. \u201cI am thrilled to welcome Ken to ACELYRIN,\u201d\u00a0said\u00a0Dr. Lin.\u00a0\u201cHe has decades of proven experience leading end-to-end commercial activities across the entire product lifecycle and has built high &hellip; Continue reading \"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-18T11:52:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0","datePublished":"2023-07-18T11:52:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/"},"wordCount":779,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/","name":"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=","datePublished":"2023-07-18T11:52:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3NjAwMCM1Njk2MjczIzIyNTg4Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelyrin-inc-appoints-ken-lock-as-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ACELYRIN, INC.\u00a0Appoints\u00a0Ken Lock as\u00a0Chief\u00a0Commercial\u00a0Officer\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/770491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=770491"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/770491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=770491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=770491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=770491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}